# A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

> **NCT07255846** · PHASE1 · WITHDRAWN · sponsor: **Terremoto Biosciences Inc.**

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia (HHT)

## Interventions

- **DRUG:** TER-1754
- **DRUG:** Placebo
- **DRUG:** TER-1754

## Key facts

- **NCT ID:** NCT07255846
- **Lead sponsor:** Terremoto Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-12-15
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This decision is based solely on internal company prioritization and resource allocation considerations. No patients have been enrolled or dosed in this study and no clinical data have been generated.
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07255846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07255846, "A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07255846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*